{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:22:35Z","timestamp":1790716955020,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/igc.0b013e3182994365","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T07:09:39Z","timestamp":1370588979000},"page":"1016-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Timing of Referral for Genetic Counseling and Genetic Testing in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Akiva P.","family":"Novetsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri A.","family":"Babb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna B.","family":"Jeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Stewart","family":"Massad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Zighelboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e3182994365_bb0005","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/IGC.0b013e3182994365_bb0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182994365_bb0015","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/IGC.0b013e3182994365_bb0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1097\/IGC.0b013e3182994365_bb0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","article-title":"BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia","volume":"124","author":"Rodriguez","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","article-title":"Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12\u201313","volume":"61","author":"Easton","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1097\/IGC.0b013e3182994365_bb0035","first-page":"767","article-title":"Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21","volume":"52","author":"Smith","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1097\/IGC.0b013e3182994365_bb0040","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2007.11.3902","article-title":"Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway","volume":"26","author":"Weberpals","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1897-4287-9-10","article-title":"Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece","volume":"9","author":"Koumpis","year":"2011","journal-title":"Hereditary Cancer Clin Pract"},{"key":"10.1097\/IGC.0b013e3182994365_bb0050","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr3172","article-title":"Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1\/2 screening to early-onset breast cancer patients","volume":"14","author":"Lee","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1097\/IGC.0b013e3182994365_bb0055","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutationYpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/01.AOG.0000187892.78392.3f","article-title":"BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?","volume":"106","author":"Cass","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0070","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1097\/IGC.0b013e3182994365_bb0075","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"10.1097\/IGC.0b013e3182994365_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2008.12.015","article-title":"BRCA1 and implications for response to chemotherapy in ovarian cancer","volume":"113","author":"Quinn","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0085","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0090","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/IGC.0b013e3182994365_bb0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-def icient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1097\/IGC.0b013e3182994365_bb0100","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0105","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/01.AOG.0000158866.68311.d1","article-title":"Subcutaneous tissue reapproximation, alone or in combination with drain, in obese women undergoing cesarean delivery","volume":"105","author":"Ramsey","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/gyno.1993.1299","article-title":"Prevention of superf icial wound separation with subcutaneous retention sutures","volume":"51","author":"Soisson","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1524-4741.2010.01027.x","article-title":"Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients","volume":"17","author":"Vadaparampil","year":"2011","journal-title":"Breast J"},{"key":"10.1097\/IGC.0b013e3182994365_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pec.2012.03.019","article-title":"Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact","volume":"89","author":"Wevers","year":"2012","journal-title":"Patient Educ Couns"},{"key":"10.1097\/IGC.0b013e3182994365_bb0125","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/GIM.0b013e3181ab2295","article-title":"Timing of BRCA1\/BRCA2 genetic testing in women with ovarian cancer","volume":"11","author":"Daniels","year":"2009","journal-title":"Genet Med"},{"key":"10.1097\/IGC.0b013e3182994365_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2008.06.016","article-title":"What women with ovarian cancer think and know about genetic testing","volume":"111","author":"Lacour","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1097\/IGC.0b013e3182994365_bb0135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/pon.1353","article-title":"A randomized trial of a breast\/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling","volume":"17","author":"Wakefield","year":"2008","journal-title":"Psychooncology"},{"key":"10.1097\/IGC.0b013e3182994365_bb0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-007-9539-2","article-title":"A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk","volume":"107","author":"Wakefield","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1097\/IGC.0b013e3182994365_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24087413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24087413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:18:29Z","timestamp":1753233509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24087413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1048891X24087413"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e3182994365","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Referral for Genetic Counseling and Genetic Testing in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e3182994365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}